Myriad Genetics (NASDAQ: MYGN) announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE